Aim: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC)
treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic …

This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024
study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell …

Pancreatic cancer (PC) is characterized by its extremely aggressive nature and ranks 14th in
the number of new cancer cases worldwide. However, due to its complexity, it ranks 7th in …

Background. In this research, programmed cell death protein 1 (PD‐1) inhibitors, including
toripalimab, sintilimab, and camrelizumab, were evaluated for the treatment of non‐small …

The rapidly expanding class of therapies targeting immune checkpoints for the treatment of
various cancers now includes 8 clinically approved agents: a LAG-3 inhibitor (relatlimab), a …

Immune checkpoint inhibitors (ICIs) became a treatment option in most tumor types and
improved survival in patients with cancer in the last decade. Older patients with cancer are …

Background: The effectiveness of immunotherapies for non-small-cell lung cancer under
real-world clinical settings remains uncertain. Materials & methods: Systematic searches of …

Objective As first-line treatment for stage IV or recurrent non-small cell lung cancer,
combination immunotherapy with nivolumab and ipilimumab, with or without chemotherapy …

Background: Immune checkpoint inhibitors (ICIs) have made a significant breakthrough in
the treatment of solid tumors; however, their use also generates unique immune-related …

The morbidity and mortality of lung cancer remain one of the highest among multiple
cancers, respectively. Small‐Cell Lung Cancer (SCLC) accounts for around 10%–15% of all …